Safety and effectiveness of oral blonanserin for schizophrenia: A review of Japanese post-marketing surveillances.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of pharmacological sciences"
DOI: 10.1016/j.jphs.2020.09.006
Abstract: Schizophrenia significantly limits social functioning with positive and negative symptoms and cognitive dysfunction. Blonanserin (LONASEN®), a novel second-generation antipsychotic approved for treating schizophrenia in Japan in 2008, reportedly shows beneficial effects on cognitive function as… read more here.
Keywords: schizophrenia; japanese post; post marketing; blonanserin ... See more keywords